HeartBeam substantially increased its total liabilities while raising additional cash, indicating active funding activities alongside growing operational commitments.
The company nearly doubled its liabilities while growing cash reserves, suggesting HeartBeam secured additional financing but also took on meaningful obligations. The 22% increase in R&D spending reflects continued investment in their cardiac monitoring technology development, though the growing liability base warrants monitoring for cash burn sustainability.
HeartBeam's balance sheet expanded meaningfully across most categories, with total assets growing 78% driven by substantially higher cash reserves. However, total liabilities roughly doubled, indicating the company took on significant new obligations even as it raised capital. R&D expenses grew modestly at 22%, showing continued but measured investment in technology development while the company manages its expanded financial structure.
Liabilities grew 99.8% — significant increase in debt or obligations, assess impact on financial flexibility.
Cash position surged 84.3% — strong cash generation or capital raise providing significant financial cushion.
Asset base grew 78.4% — expansion through organic growth, acquisitions, or capital deployment.
Current assets grew 69.1% — improving short-term liquidity or inventory/receivables build.
Equity base grew 57.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.
R&D investment increased 21.7% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →